Cholesterol and the Risk of Ischemic Stroke

Stroke

Volumn 34, Issue 12, 2003, Pages 2930-2934

  Bowman, Thomas S ^a,b,f,g   Sesso, Howard D ^b,f   Ma, Jing ^d   Kurth, Tobias ^f   Kase, Carlos S ^e   Stampfer, Meir J ^c,d   Gaziano, J Michael ^b,f  

^a HARVARD UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CHANNING LABORATORY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Massachusetts Veterans Epidemiology   (United States)

Author keywords

Cerebrovascular disorders; Epidemiology; Lipids; Risk factors; Stroke

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; COMORBIDITY; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; RISK FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 0345599228     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000102171.91292.DC     Document Type: Article

References (42)

1. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280-299.
2. Wolf PA, Kannel WB, Verter J. Current status of risk factors for stroke. Neurol Clin. 1983;1:317-343.
3. NCEP. Summary of third report of NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults III. JAMA. 2001:2486-2497.
4. Qizilbash N. Are risk factors for stroke and coronary disease the same? Curr Opin Lipidol. 1998;9:325-328.
5. Taylor WC, Landau WM. Atherosclerosis and stroke. Ann Neurol. 1990; 28:109-110.
6. Demchuk AM, Hess DC, Brass LM, et al. Is cholesterol a risk factor for stroke? Arch Neurol. 1999;56:1518-1520.
7. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke. Stroke. 2003;34:623-631.
8. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
10. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
11. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
12. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;387-392.
13. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:317-326.
14. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333-335.
15. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
16. Steering Committee of the Physicians' Health Study Research Group. Final Report on the ASA component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
17. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-1149.
18. Manson JE, Buring JE, Satterfield S, et al. Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians. Am J Prev Med. 1991;7:150-154.
19. Walker AE, Robins M, Weinfeld FD. The national survey of stroke: clinical findings. Stroke. 1981;12:113-144.
20. Berger K, Kase CS, Buring JE. Interobserver agreement in the classification of stroke in the Physicians' Health Study. Stroke. 1996;27: 238-242.
21. Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med. 2002;162:2557-2562.
22. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
23. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
24. Iso H, Jacobs DR, Wentworth D, et al. Serum Cholesterol levels and six year mortality from stroke in 350977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904-909.
25. Leppala JM, Virtamo J, Fogelholm R, et al. Different risk factors for different stroke subtypes. Stroke. 1999;30:2535-2540.
26. Koren-Morag N, Tanne D, Graff E, et al. Low and high-density lipoprotein cholesterol and ischemic cerebrovascular disease. Arch Intern Med. 2002;162:993-999.
27. Hart CL, Hole DJ, Smith GD. Comparison of risk factors for stroke incidence and stroke mortality in 20 years of follow-up in men and women in the Renfrew/Paisley study in Scotland. Stroke. 2000;31: 1893-1896.
28. Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke. 2000; 31:1882-1888.
29. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly. JAMA. 2001;285: 2729-2735.
30. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-647.
31. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med. 1998;105:48S-57S.
32. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels: the results of AFCAPS/TEXCAPS. JAMA. 1998;279: 1615-1622.
33. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
34. Sacks F, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
35. Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
36. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the 4S study. Lancet. 1994;344:1383-1389.
37. Plutzky J, Ridker PM. Statins for stroke: the second story? Circulation. 2001;103:348-350.
38. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. JAMA. 1998;279:1643-1650.
39. Rubins HB, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828-2833.
40. Stulc T, Ceska R. Cholesterol lowering and the vessel wall: new insights and future perspectives. Physiol Res. 2001;50:461-471.
41. Atiya M, Kurth T, Berger K, et al. Interobserver agreement in the classification of stroke in the Women's Health Study. Stroke. 2003;34: 565-567.
42. Callahan A. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol. 2001;88:33J-37J.